Bionano Genomics Reports 67% Spike in OGM Studies at ESHG 2026
BNGO•Bionano Genomics reported a 67% year-over-year increase in studies featuring its optical genome mapping platform at ESHG 2026, rising to 35 from 21 presentations. Authorship spanned 17 countries across five regions, with studies focusing primarily on rare and constitutional genetic disorders alongside hematologic malignancies, solid tumors and cardiovascular genomics.
1. Strong Year-Over-Year Growth
Bionano saw studies featuring its optical genome mapping platform at ESHG grow from 21 in 2025 to 35 in 2026, marking a 67% increase that underscores accelerating scientific uptake of its technology.
2. Broad Geographic Representation
Authorship expanded to 17 countries across Europe, North America, South America, Asia and the Middle East, with Europe contributing the most studies overall and Brazil emerging as the single largest national contributor.
3. Diverse Clinical Applications
Research themes included rare and constitutional genetic disorders in approximately half of the presentations, along with hematologic malignancies, solid tumors, hereditary cancer, reproductive health and cardiovascular genomics, reflecting OGM’s broad utility.
4. Integration with Complementary Technologies
Presentations showcased OGM both standalone and in combination with chromosomal microarray, classical karyotyping and long- and short-read sequencing, highlighting its role in comprehensive structural variant detection.
